ホームページ GPCR & G Protein Glucagon Receptor

Glucagon Receptor

亜型選択性的な製品

Glucagon Receptor製品

  • All (22)
  • Glucagon Receptor拮抗剤(1)
  • Glucagon Receptor作動薬(9)
  • Glucagon Receptorモジュレータ(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S3734 Albiglutide Fragment Albiglutide fragment is one copy of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9935 Teduglutide Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. Teduglutide prolongs the intestinotrophic properties of GLP-2 in animal models.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1247New Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230 Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
E7333New Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
P1231New Mazdutide (IBI362, LY330567) マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1247New Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230 Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
E7333New Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
P1231New Mazdutide (IBI362, LY330567) マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1247New Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
P1230 Retatrutide Retatrutide (LY3437943) acts as a triple agonist peptide of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R) and glucosedependent insulinotropic polypeptide receptor (GIPR). Retatrutide binds to human GCGR, GLP-1R, and GIPR with EC50 values of 5.79, 0.775 nM, and 0.0643, respectively. Retatrutide has the potential for use in research on obesity.
E7333New Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
P1231New Mazdutide (IBI362, LY330567) マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1247New Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
E7333New Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
P1231New Mazdutide (IBI362, LY330567) マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。
E4779New DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. DMB attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
P1247New Exendin-4 Exendin-4 (Exenatide) is a 39-amino acid peptide and a long-acting potent agonist of glucagon-like peptide-1(GLP-1) receptor with an IC50 of 3.22 nM. It is used in research and as a potential long-term treatment for type 2 diabetes mellitus.
Mater Today Bio, 2025, 33:102009
E7333New Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
P1231New Mazdutide (IBI362, LY330567) マズデュチド（IBI - 362；LY - 3305677）は、長時間作用型の合成オキシントモジュリン類似体です。マズデュチドはまた、グルカゴン様ペプチド受容体（GLP - 1R）とグルカゴン受容体（GCGR）の共作動薬でもあります。マズデュチドは、ヒトおよびマウスのGCGR（それぞれKi：17.7 nMおよび15.9 nM）とGLP - 1R（それぞれKi：28.6 nMおよび25.1 nM）に結合し、マウス膵島からのインスリン分泌を刺激します（EC50：5.2 nM）。マズデュチドは、肥満症および2型糖尿病（T2D）の研究に使用されます。
united states